Intuitive Surgical (NASDAQ:ISRG) Shares Down 0.6% After Insider Selling

Intuitive Surgical, Inc. (NASDAQ:ISRG) shares fell 0.6% during mid-day trading on Tuesday following insider selling activity. The stock traded as low as $589.00 and last traded at $592.23. 187,308 shares changed hands during trading, a decline of 90% from the average session volume of 1,792,521 shares. The stock had previously closed at $595.70.

Specifically, CFO Jamie Samath sold 269 shares of Intuitive Surgical stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $590.00, for a total transaction of $158,710.00. Following the sale, the chief financial officer now owns 3,282 shares of the company’s stock, valued at approximately $1,936,380. This trade represents a 7.58 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Jefferies Financial Group lifted their price objective on Intuitive Surgical from $475.00 to $575.00 in a report on Monday, January 27th. Royal Bank of Canada boosted their target price on shares of Intuitive Surgical from $611.00 to $641.00 in a research note on Monday, January 27th. Wells Fargo & Company lifted their price target on shares of Intuitive Surgical from $630.00 to $687.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Mizuho upped their target price on shares of Intuitive Surgical from $440.00 to $500.00 in a research report on Thursday, October 17th. Finally, UBS Group boosted their price objective on Intuitive Surgical from $500.00 to $560.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. One analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $613.10.

Intuitive Surgical Stock Performance

The stock has a market capitalization of $210.56 billion, a price-to-earnings ratio of 92.15, a price-to-earnings-growth ratio of 5.67 and a beta of 1.39. The business has a fifty day simple moving average of $555.91 and a 200 day simple moving average of $515.92.

Hedge Funds Weigh In On Intuitive Surgical

A number of hedge funds have recently bought and sold shares of ISRG. Thurston Springer Miller Herd & Titak Inc. grew its position in Intuitive Surgical by 19.1% during the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,158 shares of the medical equipment provider’s stock worth $569,000 after buying an additional 186 shares in the last quarter. Procyon Advisors LLC boosted its holdings in shares of Intuitive Surgical by 4.1% in the 3rd quarter. Procyon Advisors LLC now owns 6,257 shares of the medical equipment provider’s stock valued at $3,071,000 after purchasing an additional 248 shares in the last quarter. ORG Wealth Partners LLC bought a new position in Intuitive Surgical in the third quarter valued at about $65,000. Sapient Capital LLC lifted its holdings in shares of Intuitive Surgical by 2.1% in the third quarter. Sapient Capital LLC now owns 97,736 shares of the medical equipment provider’s stock worth $48,015,000 after acquiring an additional 2,002 shares during the last quarter. Finally, Affinity Wealth Management LLC bought a new position in Intuitive Surgical in the 3rd quarter valued at approximately $3,445,000. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.